News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Tuomas Tammela: Co-targeting classical cells and KRAS augments response in pancreas cancer
Photo of Tuomas Tammela from X
Jul 10, 2024, 07:19

Tuomas Tammela: Co-targeting classical cells and KRAS augments response in pancreas cancer

Tuomas Tammela, Associate Member at Memorial Sloan Kettering Cancer Center, shared on X:

“New Paper! Anupriya Singh and Hannah Styers from the lab find acute resistance to targeting KRAS in pancreas cancer is surprisingly driven by a classical epithelial state.

Co-targeting classical cells and KRAS augments response – clinically important!”

Source: Tuomas Tammela/X

A classical epithelial state drives acute resistance to KRAS inhibition in pancreas

Authors: Anupriya Singhal, Hannah C. Styers, Jonathan Rub, Zhuxuan Li, Stefan R. Torborg, Jung Yun Kim, Olivera Grbovic-Huezo, Huijin Feng, Zeynep Cagla. Tarcan, Hulya Sahin Ozkan, Jill Hallin, Olca Basturk, Rona Yaeger, James G. Christensen, Doron Betel, Yan Yan, Iok In Christine Chio, Elisa de Stanchina, Tuomas Tammela

Tuomas Tammela

Anupriya Singh Anupriya Singhal cancer Doron Betel Elisa de Stanchina Hannah C. Styers Hannah Styers Huijin Feng Hulya Sahin Ozkan Iok In Christine Chio James G. Christensen Jill Hallin Jonathan Rub Jung Yun Kim KRAS Memorial Sloan Kettering Cancer Center Olca Basturk Olivera Grbovic-Huezo OncoDaily Oncology Rona Yaeger Stefan R. Torborg Tuomas Tammela Yan Yan Zeynep Cagla. Tarcan Zhuxuan Li
Special Coverage
Blog
Jan 28, 2025, 20:25
Hung Trinh: Direct in vivo CAR T cell engineering
Career
Jan 28, 2025, 19:39
Nina Bhardwaj - Candidate for the Nominating Committee of AACR
Blog
Jan 28, 2025, 17:24
Sohila Karem: Attending the Cairo BGICC has been an incredibly enriching experience
Science
Jan 28, 2025, 17:24
Yakup Ergün: With KRAS mutations now targetable, I was reminded of our research on backbone chemotherapy selection
Blog
Jan 28, 2025, 17:24
Estela Rodriguez: Dear FDA, clinical trial diversity is not DEI
Blog
Jan 28, 2025, 17:24
Estela Rodriguez: Registration is open for the 22nd Annual PER Winter Lung Cancer Conference
Science
Jan 28, 2025, 17:24
Manel Esteller: Thrilled to introduce our article on mapping the "Hallmarks of Cancer" in human primary tumors
Blog
Jan 28, 2025, 17:23
Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25
Insight
Jan 28, 2025, 17:20
Pashtoon Kasi: Very intriguing to see differences of single agent PD1 vs combination with CTLA4
Blog
Jan 28, 2025, 17:20
Melanoma clinical trial ME17 is officially open for enrollment in Canada - Canadian Cancer Trials Group
Blog
Jan 28, 2025, 17:19
EIOC Journal Club virtual roundtable discussion on the Treatment of Endometrial Cancer
Blog
Jan 28, 2025, 17:18
Pashtoon Kasi: Positive thing to look at ASCO each year is the “incremental” gains in survival